Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going so well, why are investors so wary?